Corporate Information

Investor Relations

Press Releases

Annual and Quarterly Reports

SEC Filings

Stock Chart

Analyst Coverage

Upcoming Events

Audio Archives

Presentation Archives


Email Alerts

Information Request

Corporate Fact Sheet

Product Pipeline
Calendar of Activities
Diabetes Resources
Career Opportunities
Contact Information
This page is unavailable

Sorry, the page you have requested either does not exist or is not available at this time.
Please return to the page you came from.


These presentations contain forward-looking statements about the Company's plans which involve risks and uncertainties. The Company's actual results could differ materially from those discussed in these presentations, due to risks and uncertainties regarding the drug discovery and development process, uncertainties in the FDA process regarding review of the Company's NDA submission for Symlin, uncertainties regarding the Company's ongoing clinical studies of its drug candidates including SYMLIN, AC2993, AC3056 and AC2993 LAR, and the ability of the Company to commercialize its drug candidates, whether through sales, distribution, marketing and/or corporate partnering agreements, on terms acceptable to the Company or otherwise. Additional risks and uncertainties are described in the Company's most recently filed SEC documents, such as its Annual Report on Form 10-K for its most recent fiscal year, under the heading "Risk Factors," and its subsequently filed Quarterly Reports on Form 10-Q for the current fiscal year.